



**GMMM** Interface Prescribing  
Subgroup



**Agenda**

**8<sup>th</sup> October 2015, 1pm-3pm**

**Croft Shifa Health Centre, Belfield Road, Rochdale OL16 2UP**

[Declarations of Interest](#) (new declarations only)

Apologies: Hong Thoong, Jeanette Tilstone

	<b>ENC</b>
<b>1) Draft Minutes of 10<sup>th</sup> September 2015</b>	Item 1
<b>2) Matters Arising</b> <ul style="list-style-type: none"> <li>a) RAG List Recommendations from May meeting – now GMMM approved</li> <li>b) RAG List Recommendations from June meeting – now GMMM approved</li> <li>c) RAG List Recommendations from July meeting (melatonin &amp; antipsychotics in LD – awaiting GMMM approval)</li> <li>d) RAG List Recommendations from August meeting – comments received</li> <li>e) RAG List Recommendations from Sept meeting – currently out for comment until 31<sup>st</sup> October 2015</li> <li>f) Melatonin dose in paediatric melatonin SCP</li> <li>g) Naltrexone for opioid dependence</li> <li>h) CCG Funding arrangements for SCPs</li> </ul>	Item 2d – to follow
<b>3) Nalmefene RAG entry and info leaflet for GPs</b>	Item 3a Item 3b
<b>4) Process for GPs accepting individual patients for shared care</b>	Item 4
<b>5) Drugs requiring a review of RAG status</b> <ul style="list-style-type: none"> <li>• Methadone and Buprenorphine for opioid dependence</li> <li>• Retigabine</li> <li>• Tamoxifen and Raloxifene for chemoprevention in women at moderate and high risk of breast cancer.</li> </ul>	
<b>6) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</b> <ul style="list-style-type: none"> <li>• None</li> </ul>	
<b>7) Share Care Protocols awaiting approval at October 2015 GMMM</b> <ul style="list-style-type: none"> <li>• Ethinylestradiol for pubertal induction</li> <li>• Ciclosporin for paediatric nephrotic syndrome</li> </ul>	
<b>8) Share Care Protocols for approval – final versions for GMMM – currently out for comment</b> <ul style="list-style-type: none"> <li>• Riluzole</li> <li>• Adult ADHD</li> </ul>	

<ul style="list-style-type: none"> <li>• Melatonin in LD aged 18-55 where behavioural interventions have failed and on-going treatment in CAMHS graduates where clinically indicated.</li> <li>• Antipsychotics for challenging behaviours and learning disabilities</li> <li>• Lithium in adults</li> </ul>	
<b>9) Shared Care Protocols – drafts to go out to CCG/Trusts for comment</b> <ul style="list-style-type: none"> <li>• Lithium in paediatrics</li> <li>• Acamprosate</li> <li>• Disulfiram</li> </ul>	Item 9a Item 9b Item 9c
<b>10) Shared Care Protocols for DMARDs from Virgin Care Oldham Dermatology Secondary Care Service</b>	Item 10a Item 10b Item 10c Item 10d Item 10e Item 10f
<b>11) Updates from other groups</b>	
a) Formulary Subgroup (verbal)	
b) New Therapies Subgroup (verbal)	
c) GMMMG (verbal)	
<b>12) AOB</b>	
<b>Date of Next Meeting: 12<sup>th</sup> November 2015, 1pm-3pm, Croft Shifa Health Centre, Belfield Road, Rochdale OL16 2UP</b>	